Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis

Purpose The efficacy and safety of polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisolone (pola-R-CHP) in patients aged ≥ 80 years with untreated diffuse large B-cell lymphoma (DLBCL) remain largely unexplored. Methods In this study, we administered a reduced-do...

Full description

Saved in:
Bibliographic Details
Published in:Blood research 2025, 60(1), , pp.10-10
Main Authors: Sato, Shuku, Tsunoda, Shun, Kamata, Wataru, Togano, Tomiteru, Tamai, Yotaro
Format: Article
Language:English
Subjects:
Chemotherapy
Comorbidity
Dehydrogenases
Dementia
Frailty
Geriatrics
Health care access
Hematology
Lymphoma
Medical prognosis
Medicine
Medicine & Public Health
Oncology
Patients
병리학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!